

ASTRAZENECA PLC

Interim Financial Statements

31 March 2007



Registered number 2723534

PROFIT AND LOSS ACCOUNT
for the three months ended 31 March 2007

	Notes	31 March 2007 \$m	31 December 2006 \$m
Turnover		-	-
Operating costs		(2)	(9)
Operating loss		(2)	(9)
Income from shares in subsidiary undertakings		-	681
(Loss)/profit on ordinary activities before interest		(2)	672
Net interest	2	(7)	1
(Loss)/profit on ordinary activities before taxation		(9)	673
Taxation		(4)	(21)
Net (loss)/profit for the period/year		(13)	652
Dividends to shareholders	3	(1,885)	(2,217)
Loss retained for the period/year		(1,898)	(1,565)


STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES
for the three months ended 31 March 2007

There are no gains or losses other than those reported above (2006 nil)


BALANCE SHEET

	Notes	31 March 2007 \$m	31 December 2006 \$m
Fixed assets			
Fixed asset investments	4	17,153	19,118
Current assets			
External debtors - other		7	9
Debtors – amounts owed by subsidiaries		334	1,382
		341	1,391
Total assets		17,494	20,509
Creditors due within one year			
Short-term borrowings		(16)	(7)
Other creditors		(30)	(12)
Amounts owed to subsidiaries		(21)	(14)
		(67)	(33)
Net current assets		274	1,358
Total assets less current liabilities		17,427	20,476
Creditors due after more than one year			
Loans		(1,030)	(1,030)
Net assets		16,397	19,446
Capital and reserves			
Called-up share capital	5	378	383
Share premium account	6	1,704	1,671
Capital redemption reserve	6	76	71
Other reserves	6	1,841	1,841
Profit and loss account	6	12,398	15,480
Shareholders' funds - equity interests	7	16,397	19,446

The interim financial statements on pages 1 to 6 were approved by the Board of Directors on 25 April 2007 and were signed on its behalf by



David R Brennan
Director



Jonathan Symonds
Director

NOTES RELATING TO THE FINANCIAL STATEMENTS

1 Basis of presentation of financial information

These AstraZeneca PLC interim financial statements are presented in accordance with the accounting policies set out in the AstraZeneca Annual Report and Form 20-F Information 2006

These financial statements do not constitute statutory accounts of the Company within the meaning of Section 240 of the Companies Act 1985. Statutory accounts for the year ended 31 December 2006 have been filed with the Registrar of Companies. The auditor's report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985

2 Net interest

	31 March 2007 \$m	31 December 2006 \$m
Interest payable and similar charges		
Payable to subsidiary undertakings	(5)	(20)
External interest payable	(10)	(41)
Net exchange and hedge losses	(7)	-
	(22)	(61)
Interest receivable and similar income		
Receivable from subsidiary undertakings	15	61
Net exchange gains	-	1
	15	62
Net interest and exchange (losses)/gains	(7)	1

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

3 Dividends to shareholders

	31 March 2007 per share	31 Dec 2006 per share	31 March 2007 \$m	31 Dec 2006 \$m
2 nd interim/final	\$1 230	\$0 920	1,885	1,453
1 st interim	-	\$0 490	-	764
	\$1 230	\$1 410	1,885	2,217

4 Fixed asset investments

	Shares \$m	Loans \$m	Total \$m
Cost			
At beginning of period	6,715	12,403	19,118
Repayment of loan	-	(1,965)	(1,965)
At end of period	6,715	10,438	17,153

5 Called-up share capital

	Authorised	Allotted, called-up and fully paid	
	31 March 2007 \$m	31 March 2007 \$m	31 Dec 2006 \$m
Ordinary Shares (\$0.25 each)	378	378	383
Unissued Ordinary Shares (\$0.25 each)	222	-	-
Redeemable Preference Shares (£50,000)	-	-	-
	600	378	383

The movements in share capital during the period can be summarised as follows

	No. shares (millions)	\$m
At beginning of period	1,532	383
Issue of shares	1	-
Repurchase of shares	(21)	(5)
At end of period	1,512	378

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

6 Reserves

	Share premium account \$m	Capital redemption reserve \$m	Other reserves \$m	Profit and loss account \$m	Total 31 Mar 2007 \$m	Total 31 Dec 2006 \$m
At beginning of period	1,671	71	1,841	15,480	19,063	23,778
Net loss for the period	-	-	-	(13)	(13)	652
Dividends	-	-	-	(1,885)	(1,885)	(2,217)
Share repurchase	-	5	-	(1,184)	(1,179)	(4,129)
Share premiums	33	-	-	-	33	979
At end of period	1,704	76	1,841	12,398	16,019	19,063
Distributable reserves at end of period	-	-	1,745	3,234	4,979	6,063

At 31 March 2007 \$9,164m (31 December 2006 \$11,129m) of the profit and loss account reserve was not available for distribution. The majority of this non-distributable amount relates to profit arising on the sale of Astra AB to a subsidiary in 1999, which becomes distributable as the underlying receivable is settled in cash. During Q1 2007 \$1,965m of the profit was released by repayment. Subsequent to the period end a further repayment of \$1,528m was made on 3 April 2007 resulting in additional distributable reserves not included in the figures above. Included in other reserves is a special reserve of \$157m, arising on the redenomination of share capital in 1999.

7 Reconciliation of movements in shareholders' funds

	31 March 2007 \$m	31 December 2006 \$m
Net (loss)/gain for the period/year	(13)	652
Dividends	(1,885)	(2,217)
	(1,898)	(1,565)
Issue of AstraZeneca Ordinary Shares	33	985
Repurchase of AstraZeneca Ordinary Shares	(1,184)	(4,147)
Net reduction in shareholders' funds	(3,049)	(4,727)
Shareholders' funds at beginning of period/year	19,446	24,173
Shareholders' funds at end of period/year	16,397	19,446

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

8 Commitments and contingent liabilities

Crestor (rosuvastatin)

As previously disclosed, AstraZeneca Pharmaceuticals LP and/or AstraZeneca LP in the US were served with seven individual lawsuits in 2004 and 2005 involving alleged injury in association with the use of *Crestor*. Five of these lawsuits have now been dismissed. In addition, a motion for authorisation to institute a class action and to be a representative was filed in Quebec, Canada against AstraZeneca PLC and AstraZeneca Canada Inc, in which the petitioner alleged injury as a result of the use of *Crestor*. This matter was dismissed in March 2007. During 2006, AstraZeneca was served with six additional individual lawsuits in the US, all six of which have since been dismissed. AstraZeneca is vigorously defending all the remaining actions.